Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by LaFleur & Godfrey LLC

LaFleur & Godfrey LLC raised its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 2.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 130,373 shares of the medical equipment provider's stock after buying an additional 3,655 shares during the period. Hologic comprises about 1.3% of LaFleur & Godfrey LLC's portfolio, making the stock its 28th largest holding. LaFleur & Godfrey LLC owned approximately 0.06% of Hologic worth $9,399,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Benson Investment Management Company Inc. acquired a new stake in Hologic during the fourth quarter worth $4,832,000. Clean Yield Group raised its holdings in shares of Hologic by 18.9% in the 4th quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider's stock valued at $3,291,000 after buying an additional 7,266 shares during the period. GAMMA Investing LLC lifted its position in shares of Hologic by 17.9% during the third quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider's stock worth $312,000 after purchasing an additional 582 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Hologic by 2.9% during the 3rd quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider's stock worth $2,344,000 after buying an additional 800 shares in the last quarter. Finally, Versor Investments LP purchased a new position in Hologic in the 3rd quarter valued at approximately $1,677,000. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Stock Down 0.3 %

NASDAQ HOLX traded down $0.24 during trading hours on Monday, hitting $69.73. The company had a trading volume of 6,395,054 shares, compared to its average volume of 2,046,611. The firm's 50 day moving average is $74.84 and its 200 day moving average is $78.41. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. Hologic, Inc. has a fifty-two week low of $68.61 and a fifty-two week high of $84.67. The company has a market capitalization of $15.82 billion, a price-to-earnings ratio of 20.94, a P/E/G ratio of 2.44 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same quarter last year, the firm earned $0.89 earnings per share. The company's revenue for the quarter was up 4.5% compared to the same quarter last year. Sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Essex D. Mitchell sold 24,856 shares of the business's stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares of the company's stock, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.75% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Evercore ISI upped their price target on Hologic from $78.00 to $82.00 and gave the stock an "in-line" rating in a report on Tuesday, October 1st. StockNews.com raised shares of Hologic from a "hold" rating to a "buy" rating in a research report on Thursday, November 14th. BNP Paribas raised shares of Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Morgan Stanley reduced their price objective on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Finally, Wolfe Research began coverage on Hologic in a research report on Friday, December 13th. They issued a "peer perform" rating for the company. Seven investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Hologic currently has a consensus rating of "Moderate Buy" and a consensus target price of $88.92.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.